Glaukos Corporation (GKOS): Maintaining Hold After Channel Checks - Stifel

September 27, 2016 7:31 AM EDT
Get Alerts GKOS Hot Sheet
Price: $38.56 -2.33%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade GKOS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Stifel analyst, Jonathan Block, reiterated his Hold rating on shares of Glaukos Corporation (NYSE: GKOS) after performing a series of checks that show that the majority of docs want to be trained on CyPass, and move a subset of their MIGS procedures over to the competing suprachoroidal stent.

The analyst understands that the proposed facility increase can allow price to play a significant role for iStent in 2017 (driving both revenue and EPS), but further multiple expansion from here (currently 8x 2018 sales) will be difficult if 2017 upside is more dependent on price rather than volume due to the diminished role that price will likely play in 2018 and beyond.

Consequently the analyst is looking for a better opportunity to increase his rating in front of iDose data, Inject’s potential roll out, or Alcon's reimbursement initiatives or share gains falling short of expectations.

For an analyst ratings summary and ratings history on Glaukos Corporation click here. For more ratings news on Glaukos Corporation click here.

Shares of Glaukos Corporation closed at $38.24 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment